Evidence of a Novel Mitochondrial Signature in Systemic Sclerosis Patients with Chronic Fatigue Syndrome

Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are common in rheumatic diseases, but no studies report the frequency of these in early systemic sclerosis. There are no known biomarkers that can distinguish between patients with ME/CFS, although mitochondrial abnormalities ar...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-07, Vol.24 (15), p.12057
Main Authors: van Eeden, Charmaine, Redmond, Desiree, Mohazab, Naima, Larché, Maggie J, Mason, Andrew L, Cohen Tervaert, Jan Willem, Osman, Mohammed S
Format: Article
Language:English
Subjects:
Analysis
Chronic fatigue syndrome
Communication
Comorbidity
Development and progression
Electron transport
fatigue
Gene expression
Genes
Lung diseases
Medical research
Medicine, Experimental
Metabolism
mitochondria
Mitochondrial DNA
myalgic encephalomyelitis
Pain
Patients
Proteins
Quality of life
Scleroderma
Scleroderma (Disease)
Skin
Systemic scleroderma
systemic sclerosis
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are common in rheumatic diseases, but no studies report the frequency of these in early systemic sclerosis. There are no known biomarkers that can distinguish between patients with ME/CFS, although mitochondrial abnormalities are often demonstrated. We sought to assess the prevalence of ME/CFS in limited cutaneous SSc (lcSSc) patients early in their disease (
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241512057